A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults

Trial Profile

A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs MEDI 7510 (Primary) ; Influenza virus vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 08 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 20 Nov 2016 This trial has been discontinued in Lithuania (end date: 7 Nov 2016).
    • 18 Nov 2016 This trial has been discontinued in Latvia (end date: 7 Nov 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top